Popular Articles

Peregrine Pharmaceuticals Reports Progress In Cotara(R) Brain Cancer Clinical Program
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, provided an update on progress in the company"s clinical program for Cotara(R), a targeted monoclonal antibody-based therapy being tested in a Phase II trial as a potential new treatment for recurrent glioblastoma multiforme (GBM), a deadly form of brain cancer. The company also reported that patient enrollment in the final cohort of a second Cotara GBM trial, a dose confirmation and dosimetry study, is nearing completion and that interim data from this trial has been accepted for an oral presentation at the Society of Nuclear Medicine Annual Meeting to be held June 13-18, 2009.
generic viagra online
A Selection Of Editorials And Opinions
The Slow, Slow Pulse Of The Deliberative Body The Washington Post
News of the day
Innovia Receives FDA Clearance For The InnoPort(TM)
Innovia LLC, a privately held biomaterials-based medical device company, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration to market the InnoPort(TM) to facilitate single port access laparoscopy.
Medical Devices

Colorectal Cancer - MDC Researchers Identify Genetic Markers For Metastasis Formation

Previously, only a few genes had been associated with the formation of metastases in colorectal cancer. Now, researchers of the Max DelbrÃøck Center for Molecular Medicine (MDC) Berlin-Buch and Charité - University Medicine Berlin, Germany, have identified 115 genes that are disregulated both in the primary tumor and in its metastases. In the future, their findings may help identify patients with aggressive tumors at an earlier stage (Gastroenterology 2009, doi:10.1053/j.gastro.2009.03.041).* The National Cancer Institute estimates that, alone in the United States, 106,100 cases of colon cancer will occur and 49,920 patients will die both from colon and rectal cancer in 2009. Beginning in glands in the bowel lining, colorectal cancer often remains undiscovered initially. "However, the main problem is not the primary tumor," explained the surgeon and clinical researcher Dr. Johannes Fritzmann, "but the dangerous metastases." Metastases arise when single cells break off from the primary tumor and spread to other body regions via the blood vessels or the lymphatic system. In colorectal cancer, these cells usually settle in the liver, lungs, or lymph nodes. Since the affected patient seldom feels pain or shows other symptoms, the tumor is frequently not discovered until it has already formed metastases. To investigate which genetic mutations favor the formation of metastases, the researchers analyzed 150 tissue samples of colorectal cancer patients with and without metastases. The researchers identified 115 genes that are falsely regulated in both the primary tumors and their metastases. In this way, the researchers succeeded in identifying a genetic signature which distinguishes tumors with metastatic potential from those that do not metastasize. Of the 115 genes the researchers identified, they focused on one gene in particular: BAMBI. They discovered that this gene is more active in metastatic tumors and metastases than in non-metastatic tumors. "Our investigations show that the particular gene BAMBI is associated with two import signaling pathways and thus promotes metastasis formation," Dr. Fritzmann said. "These signaling pathways (Wnt and TGF-beta) are, among other things, important in the developing embryo." In the future the researchers want to investigate the role of the other 114 genes more closely, in order to better understand the individual steps of metastasis formation. Aim - To predict at an early stage whether the tumor will spread Dr. Fritzmann hopes the research findings will help determine early on whether a tumor has metastatic potential. The doctors could then adapt the therapy accordingly. *A Colorectal Cancer Expression Profile that Includes Transforming Growth Factor Ãÿ Inhibitor BAMBI Predicts Metastatic Potential Johannes Fritzmann1,2,6, Markus Morkel1,4,6, Daniel Besser1,6, Jan Budczies3, Frauke Kosel1, Felix H. Brembeck1,5, Ulrike Stein1,2, Iduna Fichtner1, Peter M. Schlag1,2 and Walter Birchmeier1 1 Max Delbrueck Center for Molecular Medicine, 13125 Berlin, Germany 2 Dept. for Surgery and Surgical Oncology, Charité - University Medical School, 13125 Berlin, Germany 3 Institute for Pathology, Charité - University Medical School, 10117 Berlin, Germany 4 present address: Max Planck Institute for Molecular Genetics, 14195 Berlin, Germany 5 present address: Dept. of Hematology and Oncology, University Göttingen, 37075 Göttingen, Germany 6 contributed equally. Barbara Bachtler Press and Public Affairs Max DelbrÃøck Center for Molecular Medicine (MDC) Berlin-Buch Robert-Rössle-StraÃÿe 10 13125 Berlin, Germany


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):